[go: up one dir, main page]

MX2025010920A - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
MX2025010920A
MX2025010920A MX2025010920A MX2025010920A MX2025010920A MX 2025010920 A MX2025010920 A MX 2025010920A MX 2025010920 A MX2025010920 A MX 2025010920A MX 2025010920 A MX2025010920 A MX 2025010920A MX 2025010920 A MX2025010920 A MX 2025010920A
Authority
MX
Mexico
Prior art keywords
pi3k
chemical compounds
mutants
compounds
diseases
Prior art date
Application number
MX2025010920A
Other languages
English (en)
Inventor
Chun Yu Liu
Jacob John Plattner
Dirk Andries Heerding
Matthew Alexander Perry
Peter Farina
Xianfeng Li
Stephen John Baker
Yasheen Zhou
Craig Matthew Goodwin
Sarah Ruth Jacobs
Marissa Caroline Aubrey
Gregory Lee Warren
Robert Gampe
Original Assignee
An2 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by An2 Therapeutics Inc filed Critical An2 Therapeutics Inc
Publication of MX2025010920A publication Critical patent/MX2025010920A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación proporciona nuevos derivados de boro o sus sales, composiciones que los contienen y sus usos médicos. Los compuestos son activos como inhibidores de PI3K, que incluyen mutantes de PI3K, y son útiles en el tratamiento o control de enfermedades o trastornos mediados por PI3K y sus mutantes.
MX2025010920A 2023-03-15 2025-09-15 Compuestos quimicos MX2025010920A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363452355P 2023-03-15 2023-03-15
US202363524453P 2023-06-30 2023-06-30
US202363524489P 2023-06-30 2023-06-30
US202363525623P 2023-07-07 2023-07-07
PCT/US2024/020036 WO2024192309A1 (en) 2023-03-15 2024-03-14 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2025010920A true MX2025010920A (es) 2025-12-01

Family

ID=92756066

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025010920A MX2025010920A (es) 2023-03-15 2025-09-15 Compuestos quimicos

Country Status (6)

Country Link
EP (1) EP4680612A1 (es)
CN (1) CN121219300A (es)
AU (1) AU2024234319A1 (es)
IL (1) IL323347A (es)
MX (1) MX2025010920A (es)
WO (1) WO2024192309A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779574C (en) * 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
WO2022164812A1 (en) * 2021-02-01 2022-08-04 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof

Also Published As

Publication number Publication date
EP4680612A1 (en) 2026-01-21
IL323347A (en) 2025-11-01
CN121219300A (zh) 2025-12-26
WO2024192309A1 (en) 2024-09-19
AU2024234319A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
MX2025010920A (es) Compuestos quimicos
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
GEAP202416515A (en) Quinoline compounds as inhibitors of kras
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
BR122020010667B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
AU2020231934A8 (en) Compounds useful in HIV therapy
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
MX2022001933A (es) Inhibidores de enzimas.
MX2025002705A (es) Isoquinolonas como inhibidores de pi3k
MX2024007328A (es) Inhibidores macrociclicos de btk.
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
MX2025011346A (es) Compuestos de quinolinona amida y usos de los mismos
MX2024015077A (es) Benzopirimidina-4(3h)-onas como inhibidores de pi3k
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2024012937A (es) Inhibidores del receptor del factor de crecimiento epidérmico en el tratamiento de cáncer
ZA202400821B (en) Inhibitors of transglutaminases
MX2025011886A (es) Derivados biciclicos semisaturados y usos relacionados
MX2023000198A (es) Inhibidores de atr y usos de estos.